Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sandoz Group Ltd (SDZXF – Research Report) and Spyre Therapeutics (SYRE – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Sandoz Group Ltd (SDZXF)
In a report issued on June 20, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed last Tuesday at $51.98.
Pauillac has an average return of 32.9% when recommending Sandoz Group Ltd.
According to TipRanks.com, Pauillac is ranked #1277 out of 9634 analysts.
Sandoz Group Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $50.74, a -2.4% downside from current levels. In a report issued on June 9, Barclays also maintained a Buy rating on the stock.
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics today and set a price target of $71.00. The company's shares closed last Friday at $15.01.
According to TipRanks.com, CFA is a 1-star analyst with an average return of -3.4% and a 43.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, which is a 277.9% upside from current levels. In a report issued on June 17, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
12 hours ago
- Business Insider
Analysts Are Neutral on Top Financial Stocks: Upstart Holdings (UPST), Janus Henderson Group (JHG)
Analysts fell to the sidelines weighing in on Upstart Holdings (UPST – Research Report) and Janus Henderson Group (JHG – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Upstart Holdings (UPST) Bank of America Securities analyst Mihir Bhatia maintained a Hold rating on Upstart Holdings today and set a price target of $59.00. The company's shares closed last Friday at $58.01. According to Bhatia is a 4-star analyst with an average return of 9.0% and a 61.9% success rate. Bhatia covers the Financial sector, focusing on stocks such as Bread Financial Holdings, Capital One Financial, and Synchrony Financial. Upstart Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $64.00, representing a 6.8% upside. In a report issued on June 11, Stephens also initiated coverage with a Hold rating on the stock with a $55.00 price target. Janus Henderson Group (JHG) Wells Fargo analyst Michael Brown maintained a Hold rating on Janus Henderson Group on June 20 and set a price target of $37.00. The company's shares closed last Friday at $36.72. According to Brown is a 5-star analyst with an average return of 12.5% and a 67.7% success rate. Brown covers the Financial sector, focusing on stocks such as Apollo Global Management, Raymond James Financial, and Bridge Investment Group. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Janus Henderson Group with a $39.67 average price target.
Business Insider
13 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Sarepta Therapeutics (SRPT) and Eli Lilly & Co (LLY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. Confident Investing Starts Here: Insulet (PODD) In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet. The company's shares closed last Friday at $303.15. According to Marcus is a 4-star analyst with an average return of 9.1% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $337.56 average price target, a 10.9% upside from current levels. In a report issued on June 16, Truist Financial also initiated coverage with a Buy rating on the stock with a $365.00 price target. See Insiders' Hot Stocks on TipRanks >> Sarepta Therapeutics (SRPT) In a report issued on June 20, Anupam Rama from J.P. Morgan maintained a Buy rating on Sarepta Therapeutics, with a price target of $30.00. The company's shares closed last Friday at $20.08. According to Rama has 0 stars on 0-5 stars ranking scale with an average return of -6.9% and a 37.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $44.96 average price target, implying an 115.4% upside from current levels. In a report issued on June 5, Scotiabank also upgraded the stock to Buy with a $80.00 price target. Eli Lilly & Co (LLY) Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1100.00. The company's shares closed last Friday at $762.73. According to Breen is a 2-star analyst with an average return of 0.5% and a 33.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $999.57 average price target, implying a 27.2% upside from current levels. In a report issued on June 6, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.
Business Insider
14 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sandoz Group Ltd (SDZXF – Research Report) and Spyre Therapeutics (SYRE – Research Report) with bullish sentiments. Confident Investing Starts Here: Sandoz Group Ltd (SDZXF) In a report issued on June 20, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed last Tuesday at $51.98. Pauillac has an average return of 32.9% when recommending Sandoz Group Ltd. According to Pauillac is ranked #1277 out of 9634 analysts. Sandoz Group Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $50.74, a -2.4% downside from current levels. In a report issued on June 9, Barclays also maintained a Buy rating on the stock. Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics today and set a price target of $71.00. The company's shares closed last Friday at $15.01. According to CFA is a 1-star analyst with an average return of -3.4% and a 43.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, which is a 277.9% upside from current levels. In a report issued on June 17, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.
